Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Lazertinib Formulations in Healthy Volunteers
NCT05162274Phase 1Completed
- Sponsor
- Yuhan
- Start
- Nov 2021
- Primary completion
- Jan 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lazertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Yuhan. Primary endpoints: Area Under the Curve from time zero to the last measurable concentration and Maximum Plasma Concentration. Started Nov 2021; status: completed.
02
Drugs
lazertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05162274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05162274.